Aptorum Group (APM)
Developing oncology, infectious disease, and diagnostic assets for unmet medical needs.
Something off on this page? Send us feedback.
Aptorum Group is a clinical-stage biopharmaceutical company focused on therapeutics for oncology and infectious diseases. It has narrowed operations around lead programs ALS-4 and SACT-1 while pursuing a planned DiamiR Biosciences merger that would add blood-based diagnostic capabilities.
Aptorum Group Limited is a Nasdaq-listed clinical-stage biopharmaceutical company developing therapeutic assets for diseases with unmet medical needs, especially oncology and infectious diseases. The company says it no longer provides clinical services and now concentrates its R&D resources on lead projects. ALS-4 targets bacterial virulence mechanisms linked to infections such as Staphylococcus aureus, while SACT-1 is a repurposed drug candidate initially aimed at neuroblastoma and developed through Aptorum's Smart-ACT platform.
Aptorum has also been working toward a merger with DiamiR Biosciences Corp., a private molecular diagnostics business focused on blood-based tests for brain health disorders, cancer, and related biopharma services. Execution depends on regulatory progress, clinical evidence, funding, partnerships, and completion of the proposed transaction.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $3.5M · Total assets $17.1M · Shareholders' equity $47.0K
- Revenue
- $0
- Operating income
- $1.4M
- Net income
- $1.6M
No dividends on record.
101.8K ADS (1 ADS = 8 ordinary shares) as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (101.8K in the company's Sep 3, 2026 report, 634.7K elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
CGY Investments Limited (“CGYStrategic | —17.59% of class, as filed | — | 13Dfiled Jul 11, 2019 ↗ |
Hudson Bay Capital Management LPInstitution | —6.54% of class, as filed | — | 13Gfiled Feb 7, 2022 ↗ |
Kira S. SheinermanInsider | —51.56% of class, as filed | — | 13Dfiled Jul 24, 2026 ↗ |
s: CGY Investments Limited (“CGY Investments”)Strategic | —17.59% of class, as filed | — | 13Dfiled May 8, 2019 ↗ |
s: Ian Huen (“Ian”)Insider | —69.25% of class, as filed | — | 13D/Afiled Jun 1, 2021 ↗ |
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.